{"disease":{"id":"chronic-hepatitis-c-virus-infection","name":"chronic hepatitis c virus infection"},"drugs":{"marketed":[],"pipeline":[{"drug_id":"odalasvir-25-mg","indication_name":"Chronic hepatitis C virus infection (genotypes 1–6)","indication_type":"pipeline","phase":"Phase 2","line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Odalasvir 25 mg","company_name":"Janssen Research & Development, LLC","drug_phase":"discontinued","molecular_target":"Hepatitis C virus NS5A protein","drug_class":"Direct-acting antiviral (DAA); NS5A inhibitor","quality_score":null,"revenue":null,"mechanism":"Odalasvir inhibits hepatitis C virus NS5A protein to block viral replication and assembly."}],"offLabel":[],"totalMarketed":0,"totalPipeline":1},"trials":{"data":[{"nct_id":"NCT07274345","title":"Prevalence and Risk Factors of Antiviral Resistance in Egyptian HBV Patients","phase":"","overall_status":"NOT_YET_RECRUITING","enrollment_count":2000,"lead_sponsor_name":"Amira Mohamed Zidan","has_results":false},{"nct_id":"NCT02219490","title":"A Study to Evaluate Long-term Outcomes Following Treatment With ABT-450/Ritonavir/ABT-267 (ABT-450/r/ABT-267) and ABT-333 With or Without Ribavirin (RBV) in Adults With Genotype 1 Chronic Hepatitis C Virus (HCV) Infection","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":1596,"lead_sponsor_name":"AbbVie","has_results":true},{"nct_id":"NCT04387526","title":"Sofosbuvir Plus Daclatasvir With or Without Ribavirin and Chronic HCV Genotype (GT) 4","phase":"PHASE2, PHASE3","overall_status":"COMPLETED","enrollment_count":946,"lead_sponsor_name":"Beni-Suef University","has_results":false},{"nct_id":"NCT02167945","title":"A Study to Evaluate Long-term Outcomes Following Treatment With ABT-450/Ritonavir/ABT-267 (ABT-450/r/ABT-267) and ABT-333 With or Without Ribavirin (RBV) in Adults With Genotype 1 Chronic Hepatitis C Virus (HCV) Infection","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":615,"lead_sponsor_name":"AbbVie","has_results":true},{"nct_id":"NCT04382937","title":"Ropeginterferon Alfa-2b (P1101) Phase 3 Study in Interferon Treatment-Naive Subjects With HCV Genotype 2 Infection","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":222,"lead_sponsor_name":"PharmaEssentia","has_results":false},{"nct_id":"NCT04391985","title":"Sofosbuvir/Ombitasvir/Paritaprevir/ Ritonavir and Ribavirin for Hepatitis C Virus Genotype 4 Patients","phase":"PHASE1, PHASE2","overall_status":"COMPLETED","enrollment_count":113,"lead_sponsor_name":"Beni-Suef University","has_results":false},{"nct_id":"NCT04387539","title":"ٍٍSofosbuvir/Simeprevir/Daclatasvir/Ribavirin and HCV Genotype 4-infected Egyptian Experienced Participants","phase":"PHASE1, PHASE2","overall_status":"COMPLETED","enrollment_count":94,"lead_sponsor_name":"Beni-Suef University","has_results":false},{"nct_id":"NCT02292719","title":"A Study to Evaluate the Safety and Efficacy of Ombitasvir/ABT-450/Ritonavir With Sofosbuvir With or Without Ribavirin in Adults With Chronic Hepatitis C Virus Infection","phase":"PHASE2","overall_status":"COMPLETED","enrollment_count":70,"lead_sponsor_name":"AbbVie","has_results":true}],"total":8},"guidelines":[],"source":"Drug Landscape verified database"}